Bioline RX Ltd (NASDAQ:BLRX) announced today that data on BL-8040, the Company’s leading oncology platform, have been accepted for presentations at the 58th American Society of Hematology (ASH) Annual Meeting and Exhibition in San Diego, California, taking place December 3-6, 2016.

Information on the BL-8040 abstracts presented at ASH is included below:

  • (Abstract #767) Oral Presentation: The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and their Terminal Differentiation by Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of Mir-15a/16-1 Expression; Monday, December 5, 2016, 11:30 am PST; Marriott Marquis San Diego Marina Hotel, San Diego, Ballroom AB
  • (Abstract #2745) Poster Presentation: The Selective Anti-Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, is Mediated by Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia; Sunday, December 4, 2016, 6:00-8:00 pm PST; San Diego Convention Center, Hall GH. (Original Source)

Shares of Biolinerx closed yesterday at $1.14, up $0.02 or 1.79%. BLRX has a 1-year high of $1.73 and a 1-year low of $0.71. The stock’s 50-day moving average is $0.97 and its 200-day moving average is $0.92.

On the ratings front, BLRX stock has been the subject of a number of recent research reports. In a report issued on September 23, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on BLRX, with a price target of $7.00, which represents a potential upside of 525% from where the stock is currently trading. Separately, on September 7, Maxim Group’s Jason Kolbert reiterated a Hold rating on the stock and has a price target of $1.00.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joseph Pantginis and Jason Kolbert have a total average return of 7.3% and -15.9% respectively. Pantginis has a success rate of 37% and is ranked #375 out of 4193 analysts, while Kolbert has a success rate of 28% and is ranked #4088.

BioLineRx Ltd. is a clinical-stage biopharmaceutical company. Its activities include indentifying, in-licensing, and developing therapeutic candidates. It in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical stages, and then partners with pharmaceutical companies clinical development and commercialization.